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Abstract: General anesthesia poses risks for larger zoo species, like cardiorespiratory depression, myopathy,
and hyperthermia. In ruminants, ruminal bloat and regurgitation of rumen contents with potential aspiration
pneumonia are added risks. Thus, the use of sedation to perform minor procedures is justified in zoo animals. A
combination of detomidine and butorphanol has been routinely used in domestic animals. This drug combination,
administered by remote intramuscular injection, can also be applied for standing sedation in a range of zoo
animals, allowing a number of minor procedures. The combination was successfully administered in five species of
nondomesticated equids (Przewalski horse [Equus ferus przewalskii; n ¼ 1], onager [Equus hemionus onager; n ¼ 4],
kiang [Equus kiang; n¼ 3], Grevy’s zebra [Equus grevyi; n¼ 4], and Somali wild ass [Equus africanus somaliensis; n¼
7]), with a mean dose range of 0.10–0.17 mg/kg detomidine and 0.07–0.13 mg/kg butorphanol; the white
(Ceratotherium simum simum; n¼ 12) and greater one-horned rhinoceros (Rhinoceros unicornis; n¼ 4), with a mean
dose of 0.015 mg/kg of both detomidine and butorphanol; and Asiatic elephant bulls (Elephas maximus; n¼2), with
a mean dose of 0.018 mg/kg of both detomidine and butorphanol. In addition, the combination was successfully
used for standing sedation in six species of artiodactylids: giraffe (Giraffa camelopardalis reticulata; n¼ 3), western
bongo (Tragelaphus eurycerus eurycerus; n¼2), wisent (Bison bonasus; n¼5), yak (Bos grunniens; n¼1), water buffalo
(Bubalus bubalis; n ¼ 4) and Bactrian camel (Camelus bactrianus; n ¼ 5). The mean dose range for artiodactylid
species except bongo was 0.04–0.06 mg/kg detomidine and 0.03–0.06 mg/kg butorphanol. The dose in bongo,
0.15–0.20 mg/kg detomidine and 0.13–0.15 mg/kg butorphanol, was considerably higher. Times to first effect,
approach, and recovery after antidote were short. The use of detomidine and butorphanol has been demonstrated
to be a reliable, safe alternative to general anesthesia for a number of large ungulate species.
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INTRODUCTION
Standing sedation has been used as early as the
1950s in horses.46 In zoo medicine, however,
standing sedation has been less frequently utilized
because of the perceived risk of sudden arousal as
described in domestic animals.19 However, general
anesthesia compromises the animal’s normal phys-
iologic function, causing cardiorespiratory depres-
sion, myopathy, and, in ruminants, regurgitation
and bloat.24 Furthermore, ultrapotent opioids like
etorphine have been routinely used in both captive
and free-ranging large mammals, and these drugs
can have potential severe side effects.2 Hence,
because minor, noninvasive procedures are often
performed in zoos, standing sedation could offer
an alternative to general anesthesia.27
The a2-adrenergic agonists (a2 agonists) were
developed for humans in the 1960s, but because of
their sedative effects they became popular in
veterinary medicine.22 Xylazine was the first a2
agonist to be used in horses and domestic hoof-
stock, followed by detomidine, romifidine, mede-
tomidine, and dexmedetomidine.6,11–13,18,21,23,29,50
All a2 agonists have been demonstrated to cause
cardiovascular side effects.50 The effects vary
considerably in magnitude and duration. This
can be attributed to variations in the drugs’
affinity for different receptor sites (a2 versus a1)
and subtypes of the a2 receptors (A, B, C, D).20
Medetomidine is considered to be the most
potent a2 agonist, followed by detomidine, romi-
fidine, and xylazine.21
Opioids are primarily analgesic drugs, but when
administered alone they can produce excitation.
Often they are used with a2 agonists to enhance
sedative and analgesic effects and prolong the
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period of action.16,43 Butorphanol has minimal
cardiovascular side effects and causes only mod-
erate respiratory depression.19 Its use has been
extensively investigated in combination with a2
agonists in domestic horses and hoof-
stock.19,28,32,43,47 In particular, the combination of
detomidine and butorphanol (DB) has become a
popular tool in equine practice.47
The use of xylazine has been documented for
standing procedures in yak (Bos grunniens), camel-
ids, elephants, and giraffe.1,3,8,20,31,48 An experimen-
tal a2 agonist R5 1163 was tested as a sedative in
bison (Bison bison), wapiti (Cervus canadensis), and
moose (Alces alces).40,44 Detomidine, romifidine,
and medetomidine (as sole agents) have been
sporadically used in elephant, camelids, yak, and
California sea lion (Zalopus californianus).17,33,42,45,48
In analogy to domestic animals where butor-
phanol has been added to detomidine to enhance
sedative and analgesic effects, this drug combina-
tion has also been previously used in several
larger zoo species like the African elephant
(Loxodonta africana); Grevy’s (Equus grevyi), Hart-
mann’s (Equus hartmannii), and Burchell’s zebra
(Equus burchellii); onager (Equus hemionus onager);
Przewalski horse (Equus ferus przewalskii); Nile
hippopotamus (Hippopotamus amphibius); giraffe;
and greater one-horned (GOH) (Rhinoceros uni-
cornis) and Sumatran rhinoceros (Dicerorhinus
sumatrensis).5,9,27,30,34,35,38,43,49
The present study was aimed at expanding
existing knowledge in zoo animal sedation, focus-
ing on DB. Development of doses in new species
like the kiang (Equus kiang), Somali wild ass
(Equus africanus somaliensis), Southern white rhi-
noceros (Ceratotherium simum simum), Asiatic
elephant (Elephas maximus), Western bongo
(Tragelaphus eurycerus eurycerus), wisent (Bison
bonasus), yak, water buffalo (Bubalus bubalis),
and Bactrian camel (Camelus bactrianus) and
standardization of protocols within these species
and additional species like the Przewalski horse,
onager, Grevy’s zebra, reticulated giraffe (Giraffa
camelopardalis reticulata), and GOH rhinoceros
were the main focus of the research.
MATERIALS AND METHODS
Sedation with DB was utilized over the course
of 9 yr to facilitate clinical procedures in several
zoos. Data of 14 species, mentioned above, were
analyzed retrospectively.
Animals were separated the evening before the
procedure and were fasted overnight. On the day
of the procedure, animals were locked in a stable
or outside yard, whereby disturbance was kept to
a minimum. The Asian elephant bulls were
restrained on leg chains.
Dose rates were determined from literature,
clinical records, or personal experience. The ani-
mals’ body weights were estimated based on a
database of weights. Detomidine (Medesedan, CP
Pharma, Burgdorf, 31303, Germany) and butor-
phanol (Alvegesic, Alvetra, Vienna, 1090, Austria),
were administered i.m. This was carried out using a
CO2-powered dart gun (Dan-inject JM Special,
Wildpharm, Taunton, TA4 1YX Dorset, United
Kingdom) and a plastic, compressed-air–triggered
dart (Dan-inject, Wildpharm). The two drugs were
mixed together, giving a total volume ranging from
3 to 10 ml and thereby dictating the size of the dart
used. Asian elephantswere injected i.m. with a pole
syringe (Spuit Geniaplex LL 50 ml, Val d’Hony-
Verdifarm N. V., Beringen, 3583, Belgium).
After i.m. injection, the degree of sedation was
gauged from the animal’s reaction to auditory,
visual, and tactile stimuli. Time to first effect was
calculated as the time from i.m. injection to the first
visual signs of sedation (e.g., drooping of lower lip,
salivation, ataxia). Once sedationwas deemed to be
sufficiently profound, animals were approached
and blindfolded. The absence of tail and ear
movementswere considered particularly important
for determining sedative depth. The time the
animal was approached after i.m. injection was
also recorded. If animals became recumbent after
injection, this was recorded as time to recumbency.
Any supplemental injections were also recorded.
Noise levels, the duration of each procedure,
and the number of staff involved were all kept to a
minimum. At least two human escape routes were
always accessible.
Heart rate (HR) (auscultation) and respiratory
rate (RR) (visualization of thoracic movements)
were recorded whenever possible. Arterial blood
gas and electrolyte analyses were performed in
rhinoceroses using an I-STAT portable analyzer
(Woodley Equipment Company Ltd., Horwich,
BL6 5UE, Lancashire, United Kingdom) and an I-
STATCG 8þ cartridge (Woodley Equipment Com-
pany Ltd.).
Detomidine was antagonized using atipamezole
(Atipam, Eurovet Animal Health, Bladel, 5531,
Noord-Brabant, The Netherlands). For complete
reversal, this was administered i.v. and/or i.m. at
1.5 times the dose (in milligrams) of detomidine.
Lower doses were used if only partial reversal was
desired. Additionally, butorphanol was antago-
nized with i.v. naltrexone in rhinoceros, giraffe
(2–5 mg naltrexone for each 1 mg butorphanol),
and Asian elephant (1.25–5 times the dose in
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milligrams of butorphanol). Time to recovery
(moving without ataxia, fully aware of surround-
ings, and normal reaction to external stimuli) after
administration of the antagonist was recorded
where possible. Animals were monitored until
recovery was judged to be complete. Thereafter,
keepers checked the animals at frequent intervals
over the following 2 days.
RESULTS
The doses of DB in the different species are
reported in Table 1. Times from injection to first
effect, approach, and sternal recumbency (if
relevant), as well as recovery time after adminis-
tration of the antagonist(s), are shown in Table 2,
and HRs and RRs are summarized in Table 3.
Equids
The DB protocol was used on six occasions in
four Grevy’s zebras for cast removal, clinical
examination, and blood sampling. Different doses
were administered: 40 mg detomidine and 30 mg
butorphanol (n¼ 3), 35 mg detomidine and 25 mg
butorphanol (n¼2), and 30 mg detomidine and 20
Table 1. Body weight and doses (mean 6 SD) of the combination detomidine and butorphanol in different
wildlife species as well as a recommended total dose of DB in adult animals.a
Body weight (kg)
(mean 6 SD)
Detomidine
(mg/kg)
(mean 6 SD)
Butorphanol
(mg/kg)
(mean 6 SD)
Recommended dose
of DB in adults (mg)
Grevy’s zebra (n ¼ 4) 397 6 8 0.10 6 0.01 0.07 6 0.01 40 þ 30
Onager (n ¼ 4) 263 6 25 0.11 6 0.02 0.08 6 0.01 30 þ 20
Przewalski horse (n ¼ 1) 350 0.11 0.09 40 þ 30
Somali wild ass (n ¼ 7) 232 6 18 0.17 6 0.02 0.13 6 0.03 40 þ 30
Kiang (n ¼ 3) 225 0.17 0.13 40 þ 30
Indian rhinoceros (n ¼ 4) 1,948 6 105 0.015 6 0.003 0.015 6 0.003 25 þ 25
White rhinoceros (n ¼ 12) 1,412 6 525 0.015 6 0.002 0.015 6 0.002 25 þ 25
Asian elephant (n ¼ 2) 4,400–5,500 0.018 6 0.001 0.018 6 0.001 N/A
Western bongo (n ¼ 2) 150–200 0.15–0.20 0.13–0.15 30 þ 20 (F); 30 þ 30 (M)
Reticulated giraffe (n ¼ 3) 519 6 112 0.05 6 0.01 0.03 6 0.03 30 þ 20–30
Yak (n ¼ 1) 900 0.04 0.03 40 þ 30
Wisent (n ¼ 5) 600 6 111 0.06 6 0.01 0.04 6 0.004 35 þ 25 (F); 40 þ 30 (M)
Water buffalo (n ¼ 4) 538 6 250 0.05 6 0.01 0.04 6 0.01 20 þ 15
Bactrian camel (n ¼ 5) 621 6 125 0.06 6 0.01 0.06 6 0.01 35 þ 35
a N/A ¼ not applicable; F, female; M, male.
Table 2. Times to first effect, approach, and sternal after first injection of DB i.m. and time to recovery after
administration of the antagonist(s) (all in minutes). The values are represented as mean 6 SD unless n  3.a
No. of
procedures
Time to
first effect
Time to
approach
Time to
sternal
Time to recovery
after antidote
Grevy’s zebra 6 6.2 6 1.7 18.3 6 4.6 N/A 11.7 6 7.6 (n ¼ 3)
Onager 4 5.8 6 1.7 14.3 6 2.1 N/A 2 (n ¼ 1)
Przewalski horse 2 3–4 10–21 N/A 1–2
Somali wild assb 10 4.0 6 0.3 28.7 6 12.1 N/A 8.5 6 4.1 (n ¼ 6)
Kiangc 3 4–5 N/M N/A N/M
Indian rhinoceros 4 6.8 6 1.5 29.3 6 16.9 N/A 2.0 6 0.0
White rhinoceros 14 4.9 6 1.9 13.7 6 4.2 11.5 6 4.1 (n ¼ 4) 3.0 6 2.5 (n ¼ 6)
Asian elephant 4 9.7 6 2.5 N/M N/A 4–21
Western bongo 2 5–7 13–15 N/A N/M
Reticulated giraffe 6 5.2 6 1.8 18.3 6 5.7 N/A N/M
Yakc 1 5 14 8 11
Wisent 5 4.2 6 1.3 11.2 6 4.0 N/A 5.0 6 2.9
Water buffaloc 4 5.3 6 1.7 N/M 8.3 6 0.6 (n ¼ 3) 5.0 6 1.7 (n ¼ 3)
Bactrian camel 7 6.9 6 3.2 17.7 6 6.9 N/A 15.0 6 12.5 (n ¼ 4)
a N/A ¼ not applicable; N/M, not measured.
b Large Animal Immobilon was added in eight procedures.
c Walking sedation.
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mg butorphanol (n ¼ 1). A supplemental dose of
10 mg detomidine and 5 mg butorphanol was
given twice, once after the low and once after the
median dose. All procedures were successfully
performed and recoveries were uneventful after
i.v. administration of atipamezole.
Five procedures were performed in four ona-
gers. A dose of 30 mg detomidine and 20 mg
butorphanol was used four times, whereas a dose
of 20 mg detomidine and 20 mg butorphanol was
administered once. No supplemental drugs were
required. Walking sedation was achieved three
times and standing sedation for minor procedures
was achieved twice.37 Atipamezole was either not
administered (n ¼ 2) or half (n ¼ 1) or a full dose
was given (n¼ 2).
A female Przewalski horse was satisfactorily
sedated on two occasions for blood sampling
using 40 mg detomidine and 30 mg butorphanol.
Recovery was rapid (Table 2) and smooth after i.v.
administration of atipamezole.
Seven Somali wild asses were sedated on 10
occasions. In the first five procedures, 35 mg
detomidine and 25 mg butorphanol i.m. were
used. All five animals required additional seda-
tion with 0.2–0.3 ml Large Animal Immobilon
i.m. (LAI; etorphine 2.45 mg/ml and aceproma-
zine 10 mg/ml, Novartis Animal Health UK Ltd.,
Frimley, GU16 7SR, Surrey, United Kingdom).
Two of these animals were then sufficiently
sedated for clinical examination, but one animal
had to be given naltrexone i.m. because of typical
etorphine side effects (high stepping and pacing).
Following LAI, two animals required additional
DB (5 mg of each drug) but still could not be
approached, and further attempts to achieve
sedation were abandoned. The last two animals
received 40 mg detomidine and 30 mg butorpha-
nol, followed by 0.3 ml LAI. This allowed clinical
examination and weighing of the animals. The
three previously inadequately sedated animals
were also sedated with 40 mg detomidine and 30
mg butorphanol i.m. 1 wk later. At this occasion,
only one animal required an additional 0.2 ml
LAI; the other two were sufficiently sedated to
perform clinical examination.
LAI in Somali wild ass was administered 23 6
10 min after initial DB injection when necessary.
HR, RR (Table 3), and temperature (range: 35.1–
37.18C; median: 36.58C) were monitored. Animals
received atipamezole i.v. (n ¼ 6) or i.m. (n ¼ 1). If
LAI had been administered, naltrexone (20 mg for
each 1 mg etorphine) i.v. was administered.
Recovery after i.v. administration of the antago-
nist(s) was rapid (Table 2). One animal that
received atipamezole i.m. required 62 min to
recover.
Three kiangs received 40 mg detomidine and 30
mg butorphanol i.m. for walking sedation to assist
loading. No top-ups were required while the
animals were successfully loaded. Sedation was
partially antagonized with atipamezole i.m. Ani-
mals arrived safely at the new zoo and were
unloaded uneventfully.
Rhinoceros
Four greater adult one-horned rhinoceroses
(two males, two females) were sedated using 25
mg detomidine and 25 mg butorphanol. Proce-
dures included general examination, microchip
placement, blood collection, skin biopsy, and
milking a lactating mother. Both females required
a supplemental dose (5 mg detomidine þ 5 mg
butorphanol and 10 mg detomidine þ 10 mg
butorphanol each) before they could be ap-
proached. An arterial blood sample from the
auricular artery was taken from one animal (Table
4). Recovery was uneventful after simultaneous
i.v. administration of atipamezole and naltrexone.
Twelve white rhinoceroses (five males, seven
females) were sedated successfully with DB on 14
occasions. Procedures included endoscopy of the
upper respiratory tract, microchip placement,
health checks, blood collection, reproductive
assessment via rectal ultrasound, artificial insem-
ination, and ophthalmologic examination. Accu-
rate body weights were available for six subadult
animals, and these animals received 0.015–0.017
mg/kg of both detomidine and butorphanol.
Adult animals received 25 mg detomidine and
25 mg butorphanol i.m. No supplemental drugs
were needed. On four occasions, animals went
into sternal recumbency and remained this way
Table 3. HR and RR in different wildlife species
sedated with DB i.m.a
HR
(beats/min)
RR
(breaths/min)
Grevy’s zebra (n ¼ 4) N/M 28–45 (38)
Onager (n ¼ 1) N/M 12–18
Somali wild ass (n ¼ 4) 24–60 (32) 8–42 (24)
Greater one-horned
rhinoceros (n ¼ 2)
N/M 16–36 (24)
White rhinoceros (n ¼ 5) 28–64 (44) 6–28 (14)
Western bongo (n ¼ 2) N/M 24–32 (26)
Yak (n ¼ 1) 40–50 (42) N/M
Wisent (n ¼ 5) N/M 20–36 (27)
Bactrian camel (n ¼ 4) 32–42 (40) 12–48 (16)
a Values are represented as the range and median in
parentheses. N/M indicates not measured.
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throughout the procedures. For longer proce-
dures, a catheter (20 ga) was placed in an auricular
vein to ensure intravenous access. Arterial blood
samples were taken from the ventral auricular
artery in five animals (Table 4). Procedures lasted
between 18 and 70 min. In two procedures lasting
over an hour, small doses of ketamine (100–200
mg) were administered i.v. when the animal
reacted to external stimuli. At the end of the
procedure, atipamezole was administered i.v. (n¼
12) or i.m. (n ¼ 2). One of the animals that
received atipamezole i.m. required a second dose
i.v. because the level of sedation was still deemed
to be too deep. Naltrexone (2–5 mg per mg
butorphanol) was administered together with
atipamezole i.v. (n ¼ 7) or 10 min after atipame-
zole i.v. (n¼ 3). Recovery was considerably slower
in animals receiving atipamezole i.m. (17 and 42
min) or naltrexone i.v. after atipamezole i.v. (9, 11,
and 23 min) compared to animals receiving both
antagonists i.v. together (1–7 min).
Asian elephant
An adult breeding bull (5,500 kg) had 100 mg
detomidine and 100 mg butorphanol adminis-
tered i.m. on three occasions. Effects of sedation
included wide stand, indifference to surround-
ings, and dropping of the trunk. On one occasion,
sedation was not deemed sufficient; hence, a
supplemental injection of 50 mg detomidine and
50 mg butorphanol was administered i.v. Once
sufficient sedation was achieved, ultrasonography
was performed and a good quality semen sample
was collected by manual rectal stimulation on all
three occasions. On one occasion, 100 mg atipa-
mezole alone was administered i.v. Recovery time
was not measured but recovery was uneventful.
On the other two occasions, 50 mg atipamezole
and 150 mg naltrexone i.v. were administered. A
second elephant bull (4,000 kg) received 80 mg
detomidine and 80 mg butorphanol i.m. Both
tusks were trimmed and a blood sample was
taken. Forty milligrams of atipamezole and 100
mg naltrexone were administered i.v.
Artiodactylids
A female western bongo received 30 mg
detomidine and 20 mg butorphanol, and 30 mg
detomidine and 30 mg butorphanol was adminis-
tered in a male. No supplemental drugs were
required. Clinical examination included blood
collection, intradermal tuberculin testing, and
subcutaneous insertion of a contraceptive im-
plant. Animals were not continuously monitored
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after i.m. atipamezole administration. Recovery
was sporadically checked, and both animals
recovered uneventfully.
Six procedures were performed in three giraffe
(two males, one female). A juvenile male needed
pre-export health checks including blood collec-
tion and intradermal tuberculin testing. Detomi-
dine was used as the sole agent on two occasions
(15 and 20 mg). One year later, the same animal
was successfully sedated with 30 mg detomidine
and 20 mg butorphanol. Another juvenile male
received 25 mg detomidine and 25 mg butorpha-
nol for pre-export testing. An adult female was
sedated twice for radiography of the lower limb
(30 mg detomidine and 25 mg butorphanol and 30
mg detomidine and 30 mg butorphanol). On both
occasions radiography was successful but blood
collection was possible only at the higher butor-
phanol dose. No physiologic data were recorded
during the procedures. In the first male, no
antagonist was administered (no ataxia observed).
In the second male, only atipamezole was admin-
istered i.m., and in the female, atipamezole and
naltrexone were administered together i.m. on
both occasions. After the procedures, giraffes
recovered in an outdoor concrete yard. Recovery
was estimated to be complete within 15–25 min
after administration of the antagonist(s).
An adult male yak was sedated with 40 mg
detomidine and 30 mg butorphanol for walking
sedation during loading. Initially the yak went
into sternal recumbency. After stimulation, the
animal stood up and walked into the trailer.
Movements were ataxic but balance was never
lost and the yak was loaded uneventfully.26
Atipamezole i.m. was administered after loading,
and the yak had regained full consciousness
within 11 min (Table 2), allowing transport to
start.26
Five wisents (one male, four females) were
sedated to allow diagnostic swabs forMycoplasma
identification. Pregnancy diagnosis, using rectal
palpation, was also performed. Females received
35 mg detomidine and 25 butorphanol, and the
male had 40 mg detomidine and 30 mg butorpha-
nol administered. No additional doses were
required. The cows received atipamezole i.v.,
whereas the bull received half the dose i.m. and
the other half i.v. All animals recovered unevent-
fully after atipamezole injection (Table 2).
DB was used for walking sedation to translo-
cate four water buffaloes. Three out of four
animals went into lateral recumbency 6–8 min
after injection. Open castration was performed on
two recumbent males. A large adult male (900 kg)
who received 40 mg detomidine and 30 mg
butorphanol was partially antagonized with 10
mg atipamezole i.v., which allowed the animal to
stand up 3 min after injection and walk blindfold-
ed into a trailer. A young male (350 kg) and an
adult female (400 kg) received 25 and 20 mg
detomidine respectively and 15 mg butorphanol
i.m. and then both received 5 mg atipamezole i.v.
to stand up and walk in the container. The fourth
animal (500 kg) received 20 mg detomidine and 15
mg butorphanol i.m. and walked into the contain-
er without difficulties. None of the animals
received (additional) atipamezole after unloading.
DB has been used on seven occasions in four
adult Bactrian camels. On five occasions 35 mg
detomidine and 35 mg butorphanol were used
with satisfactory results. On two occasions 30 mg
detomidine and 30 mg butorphanol were admin-
istered, but a supplemental dose of 10 mg
detomidine and 10 mg butorphanol was required
in one of these cases. All animals remained
standing. Radiography, treatment of myiasis,
blood collection, and insertion of a microchip
were successfully performed. All but one animal
received atipamezole i.m. Time to recovery is
recorded in Table 2.
DISCUSSION
Sedation with DB allowed safe procedures in
(mostly) standing animals, for both handlers and
animals. The data collected allowed standardiza-
tion of the initial sedative doses in all species
tested (Table 1).
Regarding staff safety, the authors recommend
use of enclosures with at least two accessible
doors to safely approach an animal from behind
and to have an escape route in case of sudden
arousal. A thorough briefing before the procedure
is necessary to explain the possible risks of
entering an enclosure with a semiconscious ani-
mal. Staff numbers in the enclosure and external
stimuli should be kept to an absolute minimum so
as not to unnecessarily stimulate the animal.
All equids showed signs of a2 agonist–butor-
phanol sedation similar to those seen in domestic
horses: indifference to the surroundings, lowering
of the head, drooping of the eyelids and lower lip,
and ataxia.19 Absence of tail and ear swishing was
considered to be the most reliable means to
determine whether animals could be approached
safely.
Dose rates administered in Grevy’s zebra were
lower when compared with dose rates reported in
literature (Table 5). Previously, butorphanol has
been administered 10 min after detomidine be-
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cause of the occurrence of a minor excitation
when these drugs were administered together.27
Excitation was not seen in the present study even
though DB was administered together in one dart.
It is likely that the excitation described previously
might be a result of the higher dose of butorpha-
nol used, as opioids are known to produce
excitatory effects in horses.14,27
None of the zebras in the present study
required incremental doses to deepen sedation,
whereas, as reported previously, one-third of the
study animals required additional LAI to produce
adequate sedation.27 The need for additional LAI
in those study animals contributed to the nervous
character of the animals during repeated proce-
dures over a short time period.27 Zebras in the
present study were generally calm animals, but
repeated procedures were also performed. Two
animals had cast changes, and although the
plaster saw produced considerable noise and
vibration the animals remained well sedated. An
earlier study, using DB with both drugs adminis-
tered together, described good sedation in
Grevy’s zebras, allowing hoof trimming and
minor surgery.30 Hence, it is most likely that the
differences in the initial dosing protocol, as
mentioned above, contributed to a deeper level
of sedation in the current study.
The doses used in onager and Przewalski horse
in the present study were considerably lower than
the one reported in the literature (Table 5). Even
at the higher doses reported in literature, it was
suggested that the combination would be suitable
only for transport in onagers.30 Notwithstanding,
the current results show that minor procedures
could also be performed. A possible explanation
could be that the onagers and Przewalski horses
in this study were accustomed to human contact
and confined spaces and hence these animals
might have been calmer before sedation, reducing
the need for high doses of the DB protocol while
still achieving an acceptable level of sedation.
Use of DB in Somali wild ass has not previously
been reported. Based on the lead author’s expe-
rience, Somali wild ass is accepted to be the most
aggressive and nervous equid, followed by kiang,
onager, Przewalski horse, and zebra. Therefore,
higher doses than those used in other equids were
necessary, as well as the option of giving incre-
mental LAI. When the higher LAI doses (0.3 ml)
were used, the animals could easily be approached
but were severely head pressing, as described
previously in zebras.27 Therefore, the authors
suggest limiting doses to 0.2 ml LAI or less in
this species after DB sedation. A push board was
used in the last two procedures, allowing animals
to be cornered and blindfolded safely, whereby
signs of a flight response disappeared, enabling
the procedures to go ahead without the need of
LAI.
To the authors’ knowledge, the use of DB in
kiang has also not been reported previously. In
anticipation of their nervous character and with
the earlier experience of the Somali wild ass
procedures, it was decided to give a dose at the
high end of the equid dose range.
Onset of sedation in general was faster than
previously reported.30 Approach time in the
present study was similar in zebra, onager, and
Przewalski horse but was much longer in Somali
wild ass, presumably as a result of their nervous
nature.
HRwas monitored only in Somali wild ass. The
anticipated typical second-degree atrioventricular
blocks and bradycardia were observed.12,19 It can
only be assumed that in the other equid species
similar changes might also have occurred.
Route of administration of the antagonist(s)
(i.v. vs. i.m.) depended on several factors, includ-
ing the nature of the individual, level of sedation
Table 5. Reported i.m. dose rates of detomidine (D) and butorphanol (B) in several wildlife species.
D þ B (mg/kg) Reference Comments
Zebra D: 0.10–0.15 þ B: 0.14–0.2 27 2.45 lg/kg etorphine þ 10 lg/kg
acepromazine in excited animals
Grevy’s zebra D: 0.11–0.23 þ B: 0.1–0.15 30 Minor surgical procedures possible
Onager D: 0.24–0.27 þ B: 0.15–0.19 30 Restraint was not possible
Przewalski horse D: 0.12–0.27 þ B: 0.06–0.12 30 Fatality in 1 case
Rhinoceros D: 0.03 þ B: 0.015 7 Sufficient for minor procedures
Indian rhinoceros D: 0.013–0.015 þ B: 0.025–0.033 5 Body weight not mentioned in manuscript
(calculated on 2,000 kg)
African elephant D: 0.129–0.197 þ B: 0.121–0.197 35 Mild gastrointestinal side effects in 5
procedures
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required after the procedure, and level of sedation
at the end of the procedure. In general, i.v.
administration was preferred in order to have
immediate reversal, and no signs of excitement
were seen when using this route. However,
nervous equids and animals undergoing transport
or benefiting from a more gradual recovery (e.g.,
cast changes) were reversed either i.m. or half i.m.
and half i.v. Animals that were deemed to have
sufficiently recovered did not receive antidotes. It
was also decided not to antagonize butorphanol,
in contrast to an earlier study, as this was not
deemed necessary.27
The doses in both rhinoceros species were
compared with doses reported in literature (Table
5). Two studies described higher doses, whereas a
third study used a similar dose.5,7,25 Signs of
sedation were similar in both species of rhinocer-
os and similar to those reported in equids:
animals became ataxic and unaware of their
surroundings; the head and neck were lowered,
almost touching the ground; the ears stopped
flicking; and the eyelids and lower lip drooped.
Two female GOH rhinoceroses needed an
incremental DB dose before approach. One
female reacted on impact of the dart by charging
towards the fence. The other female was separat-
ed from its neonate calf before sedation, causing a
degree of distress.41 It is very well known that
stress and the associated release of the aspecific
a2–a1 agonists epinephrine and norepinephrine
reduces efficacy of a2-agonistic drugs by blocking
a adrenoreceptors, and therefore it is important to
consider the nature of the individual animals in
determining the detomidine dose.36 The addition
of small doses of ketamine (100–200 mg i.v.)
seemed to deepen the level of standing sedation
in the white rhinoceroses, as described previous-
ly.25
Of the four white rhinoceroses that went into
sternal recumbency, three were male. Male rhi-
noceroses sedated with azaperone–butorphanol
were also reported to go into sternal recumbency,
whereas females remained standing.39 This might
indicate that male rhinoceroses act differently to
sedative drugs, but, with only a small data set, this
will need further investigation. Times to first
effect in the present study were comparable to
those for rhinoceroses sedated with azaperone–
butorphanol.39 The longer time to approach in the
GOH rhinoceros was because of the supplemental
doses needed in the nervous females, as men-
tioned above.
Cardiopulmonary parameters have been deter-
mined in unrestrained, unsedated white rhinocer-
oses (mean HR: 39 beats/min; range: 32–42
beats/min).10 Based on these reference values,
bradycardia was observed only in one animal
during one measurement. This is somewhat
surprising, as bradycardia is anticipated with a2
agonists.12,19 However, it should not be excluded
that the effect of darting and afterwards the
movement around the animals caused a stress
reaction leading to an increased HR.
The normal mean RR in white rhinoceros was
reported at 19 breaths/min (range 16–23 breaths/
min).10 Compared to these values, most white
rhinoceroses in the present study were bradyp-
neic. It has been shown that a2 agonists cause
some respiratory depression in other species and
that butorphanol may slightly increase this respi-
ratory depression.19 The values seen were compa-
rable to RRs seen in rhinoceroses sedated with
azaperone–butorphanol (mean RR: 14.7 breaths/
min; range: 9–31 breaths/min), which might
indicate that, in rhinoceros, respiratory depres-
sion is mainly attributable to butorphanol.39
Reference values for RR in conscious GOH
rhinoceroses have not been reported, but it can
only be assumed that they are comparable to
those of white rhinoceroses. Based on these
values, tachypnea was observed in two females
and mainly during times of external stimuli, which
might indicate that this was stress or pain related.
RR in this study was higher than in GOH
rhinoceroses sedated with detomidine (20–30
mg) and butorphanol (50–60 mg) (7.1 6 2.4
breaths/min) in a different study.5 In the latter
study, the dose of butorphanol was double or
more than the dose used in this study, which
might explain the much lower RR due to opioid-
related respiratory depression.5
When atipamezole was administered alone, it
was observed that rhinoceroses remained moder-
ately sedated unless naltrexone was administered.
This implies that butorphanol has strong sedative
effects in rhinoceros and needs to be antagonized
if immediate and complete reversal of sedation is
preferred.
DB in the Asiatic elephant bulls produced
satisfactory sedation and animals remained stand-
ing, similar to African elephants sedated with a
DB protocol (Table 5). The addition of naltrexone
to antagonize butorphanol seemed to produce a
quicker, more stable antagonism even with rela-
tively low doses of atipamezole. Hence, the
authors would recommend antagonizing butor-
phanol in this species if complete and/or rapid
reversal of sedation is preferred. A total dose of
the DB combination is not listed in Table 1 for
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elephants as the weight differences between
individual elephants are too large. However, the
dose of each drug in milligrams per kilogram is
very consistent in this species and can be safely
used.
The present study reports the use of DB for the
first time in several artiodactylid species. The
dose rates across these species were comparable
(Table 1) except for bongo, which needed much
higher doses. Bongo in this study were extremely
nervous, hence requiring an increased dose to
reach satisfactory sedation.
Signs of sedation in most artiodactylid species
were similar to those seen in domestic cattle and
included lowering of the head and neck, drooping
of the lower lip and ears, ataxia, and salivation. In
camels, signs of sedation slightly differed, as
instead of the head’s being lowered, it was raised
upwards and backwards for support against the
hump.
Because giraffes can injure their handlers by
kicking or swaying their neck, they were walked in
a runway and were locked between two sliding
doors to provide additional physical restraint.
Giraffe are a high-risk species for anesthesia, and
fatalities are not uncommon; hence, the develop-
ment of a good sedative protocol is of major
importance.4 Furthermore, giraffe in captivity are
often chronically stressed and subclinically dis-
eased because of suboptimal dietary requirements
potentially increasing the risk of anesthesia.15 DB
appears to offer a safe alternative in giraffe for
different noninvasive procedures that previously
required general anesthesia.
CONCLUSIONS
DB i.m. offers a safe option, for both animals
and handlers, for sedation in different zoo
ungulates. As demonstrated in some individuals
of the species in the study, e.g., the Somali wild
ass, dose rates may need to be adjusted to
develop a species-specific regime, and in some
there may be a need to add increments of these or
other agents to facilitate safe interventions. No
adverse reactions were observed for any of the
animals in the study, from induction to full
recovery.
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